Amag Pharmaceuticals Inc.

A firestorm over pricing, a failed confirmatory trial and more than $1.5B in sales mark preterm birth drug’s 12-year journey from accelerated approval

Plus: Myers at the helm of Viridian, and updates from Novartis, 

Plus: Estigarribia becomes InterVenn CEO and updates from Lyndra, Catalio, Pneumagen and more

Plus: Allogene’s Amado joins Zai Lab, and updates from bluebird bio, Rejuvenate, Novadip and more

Plus Turtle leaving BridgeBio, and updates from Clover, Y-mAbs, Genenta and more

Company seeking syndicate for series B

Plus: Arcturus, BioDelivery, Landmark Bio, Vitrolife, Novome and more

Preterm birth drug has long been focus of drug pricing, efficacy concerns

Dong Yu joined vaccine developer Dynavax Technologies Corp. (NASDAQ:DVAX) as SVP of vaccine research. Yu was previously head of preclinical R&D U.S. at GlaxoSmithKline plc (LSE:GSK;

Updates on Russia’s latest COVID-19 vaccine approval and more